Technical Analysis for CHRO - Chromocell Therapeutics Corporation
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | N/A | N/A | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 6.67% | |
| NR7 | Range Contraction | 1.91% | |
| Narrow Range Bar | Range Contraction | 1.91% | |
| Inside Day | Range Contraction | 1.91% | |
| Wide Bands | Range Expansion | 1.91% | |
| Oversold Stochastic | Weakness | 1.91% | |
| MACD Bullish Signal Line Cross | Bullish | 2.56% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 16 hours ago |
| Rose Above Previous Day's High | about 18 hours ago |
| Outside Day | about 18 hours ago |
| Up 10% | about 18 hours ago |
| 60 Minute Opening Range Breakout | about 19 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound is CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as for the treatment of eye pain and neuropathic pain. The company was founded in 2002 and is based in Freehold, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Neuropathic Pain Erythromelalgia Sodium Channel Blockers
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Neuropathic Pain Erythromelalgia Sodium Channel Blockers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.0 |
| 52 Week Low | 1.22 |
| Average Volume | 26,733 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 1.89 |
| 10-Day Moving Average | 1.62 |
| Average True Range | 0.31 |
| RSI (14) | 38.65 |
| ADX | 59.73 |
| +DI | 13.38 |
| -DI | 26.39 |
| Chandelier Exit (Long, 3 ATRs) | 1.82 |
| Chandelier Exit (Short, 3 ATRs) | 2.14 |
| Upper Bollinger Bands | 2.61 |
| Lower Bollinger Band | 1.17 |
| Percent B (%b) | 0.3 |
| BandWidth | 76.07 |
| MACD Line | -0.41 |
| MACD Signal Line | -0.45 |
| MACD Histogram | 0.0372 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.05 | ||||
| Resistance 3 (R3) | 2.06 | 1.92 | 1.98 | ||
| Resistance 2 (R2) | 1.92 | 1.81 | 1.92 | 1.95 | |
| Resistance 1 (R1) | 1.76 | 1.73 | 1.84 | 1.75 | 1.93 |
| Pivot Point | 1.62 | 1.62 | 1.66 | 1.61 | 1.62 |
| Support 1 (S1) | 1.46 | 1.51 | 1.54 | 1.45 | 1.27 |
| Support 2 (S2) | 1.32 | 1.43 | 1.31 | 1.25 | |
| Support 3 (S3) | 1.16 | 1.32 | 1.22 | ||
| Support 4 (S4) | 1.15 |
